Literature DB >> 19819015

JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones.

L Sokol1, G Caceres, K Rocha, K J Stockero, D W Dewald, A F List.   

Abstract

The 2008 World Health Organization (WHO) proposed revision of the classification of MDS recognizes a deletion (5q) subtype with mutation of Janus kinase-2 (JAK2(V617F)). We investigated the clonal origin of this gene mutation in a patient with del(5q) MDS presenting with thrombocytosis and normal hemoglobin. Analysis of colony forming units-granulocyte-monocyte (CFU-GM) and erythropoietin-independent growth of bone marrow (BM) and peripheral blood (PB) burst forming units-erythroid (BFU-E) showed that del(5q) and JAK2(V617F) existed in progenitors derived from independent clones. Fifty percent of endogenous erythroid colonies (EEC) harbored the JAK2(V617F) mutation whereas fluorescent in situ hybridization (Fish) with a chromosome 5 (q31.1) probe showed only a diploid allele compliment. Assessment of transcriptional clonality by iduronate-2-sulfatase (IDS) gene polymorphism suggested that JAK2(V617F) was acquired in at least two independent multipotent stem cell progeny. Our findings indicate that JAK2(V617F) mutant clones may arise in genetically discordant clones independent of del(5q). Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19819015     DOI: 10.1016/j.leukres.2009.09.016

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

1.  Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Authors:  Marta Fernandez-Mercado; Adam Burns; Andrea Pellagatti; Aristoteles Giagounidis; Ulrich Germing; Xabier Agirre; Felipe Prosper; Carlo Aul; Sally Killick; James S Wainscoat; Anna Schuh; Jacqueline Boultwood
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

2.  Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment.

Authors:  Eleftheria Hatzimichael; Konstantinos Lagos; Amalia Vassou; Dora Gougopoulou; Alexandra Papoudou-Bai; Evangelos Briasoulis
Journal:  Mol Clin Oncol       Date:  2016-04-20

3.  WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.

Authors:  M M Patnaik; T L Lasho; C M Finke; N Gangat; D Caramazza; S G Holtan; A Pardanani; R A Knudson; R P Ketterling; D Chen; J D Hoyer; C A Hanson; A Tefferi
Journal:  Leukemia       Date:  2010-05-20       Impact factor: 12.883

4.  Diagnosis of del(5q) MDS, 14 Years after JAK-2 Positive PV Appearance: Complete Remission of both Diseases with Lenalidomide Monotherapy.

Authors:  Antonella Vaccarino; Irene Dogliotti; Fabio Marletto; Andrea Demarchi; Mario Bazzan
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-20       Impact factor: 2.576

5.  Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study.

Authors:  Benoit de Renzis; Veronique Mansat-De Mas; Eric Wattel; Odile Beyne-Rauzy; Laurent Knoops; Aurélie Cabrespine; Zahia Azgui; Lionel Ades; Jean-Jacques Kiladjian; Pierre Fenaux
Journal:  Leuk Res Rep       Date:  2013-08-30

Review 6.  Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.

Authors:  Pellegrino Musto; Vittorio Simeon; Roberto Guariglia; Gabriella Bianchino; Vitina Grieco; Filomena Nozza; Francesco La Rocca; Gioacchino Marziano; Anna Vittoria Lalinga; Emiliano Fabiani; Maria Teresa Voso; Patrizia Scaravaglio; Cristina Mecucci; Giovanni D'Arena
Journal:  Onco Targets Ther       Date:  2014-06-13       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.